GJB2 and breast carcinoma: As such, we expanded our survival analysis using the Kaplan–Meier (KM) plotter (http://kmplot.com/) and found that Cx26 did not predict significant differences in relapse-free survival in any breast cancer subtype (Supplementary Fig. 13b).